The US Central Lab market is undergoing significant transformation driven by technological advancements, increasing complexity in clinical trials, and the growing need for specialized laboratory services. Expected to expand at a healthy CAGR of 7.9% from 2024 to 2035, the market was valued at USD 2,850 million in 2025 and is projected to reach USD 5,938 million by 2035. The report provides a comprehensive outlook on key market dynamics, top drivers, trends, opportunities, recent developments, and regional market share distribution.
The economic impact of tariffs on "US Central Lab".
US Central Lab Market Growth Drivers
Advancements in Digital Pathology and Data Integration: Companies such as Labcorp and Covance are leveraging digital pathology, AI-based image analytics, and cloud-enabled data platforms to enhance the efficiency and reliability of laboratory services. These technologies facilitate real-time data access and remote diagnostics, allowing pharma sponsors and CROs to streamline multi-site clinical trials. The integration of data from various sources, including genomics and biomarkers, is driving demand for central labs capable of advanced data management and analytics.
Increasing Complexity and Volume of Clinical Trials: The rise of precision medicine, rare disease research, and a growing number of biologics in the drug pipeline necessitate highly specialized laboratory services. Central labs like Quest Diagnostics are responding with expanded test menus, advanced biomarker development capabilities, and logistical support for decentralized or hybrid trial models. The increasing regulatory scrutiny around data integrity and trial outcomes further boosts the role of established central labs in ensuring compliance and consistency.
US Central Lab Market Trends
Adoption of Decentralized and Hybrid Clinical Trial Models: The shift toward decentralized and hybrid clinical trials, accelerated by the COVID-19 pandemic, is supporting new business models for central labs. For instance, LabConnect has expanded its at-home sample collection and mobile phlebotomy networks, allowing for more flexible patient participation and reducing site visits. This trend has compelled central labs to invest in logistics, digital tracking, and remote data capture to maintain sample integrity and data quality.
Expansion of Biopharma Outsourcing and Strategic Partnerships: Biopharma sponsors are increasingly outsourcing central laboratory services to specialized providers to focus on core competencies and meet tight regulatory timelines. Recent strategic partnerships, such as IQVIA's collaboration with Medable for integrated lab-data management platforms, exemplify this trend. These partnerships drive innovation and improve end-to-end service offerings, from sample logistics to real-time analytics and regulatory compliance support.
US Central Lab Market Opportunities
Expansion in Biomarker and Genomic Testing: The rise of precision medicine is creating opportunities for central labs to expand their biomarker and genomic testing capabilities. Companies like Covance are investing in NGS and multiplex assay services to cater to complex trial protocols, opening new revenue streams and service models.
Emergence of Artificial Intelligence and Automation: The application of AI-driven data analytics and workflow automation provides opportunities for central labs to improve operational efficiency, reduce turnaround times, and enhance result accuracy, which attract more trial sponsors.
US Central Lab Market Revenue (USD Million), 2020-2035
The chart demonstrates steady and robust growth in the US Central Lab market from 2020 to 2035. Starting at USD 1,800 million in 2020, the market shows a consistent upward trajectory, reaching USD 2,850 million by 2025. Post-2025, the growth accelerates, fueled by the rise in complex clinical trials and adoption of new technologies, leading to a projected market size of USD 5,938 million by 2035. The CAGR of 7.9% highlights strong investor confidence and ample market opportunities driven by both biopharma innovation and regulatory dynamics. The growth curve reflects increasing demand for specialized testing, advanced analytics, and expanded service offerings.
US Central Lab Market Share by Region, 2025
The pie chart displays US Central Lab market share distribution by major regions for 2025. The Northeast leads the market with a 38% share owing to the concentration of biopharmaceutical research hubs and academic medical centers in states like Massachusetts and New York. The Midwest follows with an 18% share, driven by clinical research clusters in Illinois and Minnesota. The South holds a 17% share, with Texas and North Carolina prominent for large research institutions. The West region captures a 15% share, with California, particularly the Bay Area and San Diego, serving as innovation centers. Other regions collectively contribute 12%, mainly through emerging research organizations and smaller contract labs.
US Central Lab Recent Developments (Past 6 months)
In April 2024, Labcorp expanded its central laboratory facilities with the opening of a new state-of-the-art genomics and precision medicine laboratory in San Diego, featuring advanced next-generation sequencing capabilities and integrated digital pathology platforms. This expansion aims to support increasing demand for complex biomarker assays in oncology and rare disease clinical trials.
In May 2024, Quest Diagnostics announced a strategic alliance with a leading decentralized clinical trial (DCT) technology provider to enhance remote specimen collection and real-time data integration. The agreement strengthens Quest’s position in the fast-evolving DCT market, providing scalable laboratory support for hybrid trial designs and improving patient outreach.
In February 2024, Parexel introduced a new sample tracking and analytics platform in partnership with Oracle Health Sciences, enabling real-time tracking of biospecimens across multiple trial sites. The platform leverages AI for predictive logistics and analytics to optimize turnaround times and minimize data errors, thus improving trial efficiency for biopharmaceutical clients.
Press Releases